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INTRODUCTION
Aplastic anemia (AA) is a term describing pancytopenia
with hypo-plastic marrow. AA is linked to exposure to
benzene, pesticides and other chemicals. Marrow failure
is a severe idiosyncratic complication due to the use of
certain medical drugs. It can follow specific viral
infections, as in postseronegative hepatitis.1
The incidence of this disease has been found to be low
in prospective studies from the United Kingdom, France,
Brazil, and in the International Agranulocytosis and
Aplastic Anemia Study (IAAAS) conducted in several
European countries as well as in Israel.2
In addition, the incidence of aplastic anemia shows
geographical variability. It seems to be lower in Europe,
North America and Brazil, and higher in Asia. Based on
the two epidemiological studies carried out in Europe
and Asia that used the same methodology, the incidence
of the disease is two to three fold higher in Asia than in
the West. This variability in incidence rates may reflect
differences in exposure to environmental factors
including viruses, drugs and chemicals, genetic
background, diagnostic criteria, and study designs.3
Severe aplastic anemia (SAA) can occur at any age. In
children it is either acquired, idiopathic or is a
consequence of a range of genetic disorders.4 Outcome
of patients with SAA has considerably improved over the
last couple of decades with the better supportive care
and advances in treatment modalities. The preferred
treatment for children with AA is haematopoietic stem
cell transplantation (HSCT) from a human leukocyte
antigen (HLA) - identical sibling. This results in
approximately 90% cure rates.4 The alternative
treatment for patients without a HLA identical donor is
an immunosuppressive therapy (IST). This has shown
75% cure rates.5 A lot of  Western data is available on
aplastic anemia, but very few studies are found from the
Indian sub-continent. 
The aim of this study was to present the data regarding
the clinicohaematological features, the important
treatment modalities being given and their outcomes.
ABSTRACT
Objective: To determine the clinicohaematological features, treatment and outcome of children diagnosed with aplastic
anemia at a single institution.
Study Design: Observational study.
Place and Duration of Study: The Aga Khan University Hospital, Karachi, from January 1999 till December 2008.
Methodology: Medical records of children aged less than 15 years of age diagnosed with aplastic anemia were reviewed.
Clinicohaematological features, treatment and its response to therapy and outcome were recorded. Results were
described in percentages.
Results: Ninety patients were diagnosed to have aplastic anemia (AA); 65 were male during the study period. Age ranged
from 1 to 15 years. Fever in 65 patients (72.2%), pallor in 53 (58.8%), skin bleeding in 49 (54.4%) and epistaxis in
31(34.4%) were the most common and frequent presenting features. Congenital (Fanconi’s) anemia was found in 15
(16.6%) and acquired idiopathic in 75 (83.4%) of patients. Very severe aplastic anemia (VSAA) was seen in 29 (32.2%),
26 (28.9%) had severe AA and 17 (18.9%) had moderate AA. Eight patients (8.9%) underwent haematopoietic stem cell
transplantation (HSCT), 12 (13.3%) received immunosuppressive therapy (IST) and 70 patients (77.7%) received other
and supportive therapy. Five (62.5%) patients showed complete response to HSCT and 3 (37.5%) failed to engraft. IST
showed complete response in 3 (25%), partial response in 5 (41.6%) and no response in 4 (33.3%). Twenty two patients
(24.4%) expired either due to infection in 16 (72.7%, fungal in 6, bacterial in 10) and intracranial haemorrhage in 6 (27.3%)
cases. 
Conclusion: Majority of cases with AA were acquired and idiopathic in etiology. VSAA and SAA were frequent. Response
to HSCT and IST was sub-optimal.
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METHODOLOGY
The charts of children less than 15 years of age from the
year 1999 till 2008 were studied at the Aga Khan
University Hospital, Karachi. The selection of patients
was based on the diagnosis of aplastic anemia
confirmed by bone marrow trephine biopsy. The data
collected by chart review included age, gender, date of
diagnosis, prior treatment, clinical features, family
history, complete blood count, bone marrow aspirate
and trephine biopsy features, chromosomal breakage
studies, hepatitis B and C serology, treatment options,
complications, response and outcome.
Patients were classified according to proposed criteria
for the disease severity. Aplastic anaemia was
considered severe (SAA) if the marrow cellularity was
< 25%, with at least 2 of either neutrophil count < 0.5 x
109/L or platelet count < 20 x 109/L or reticulocyte count
< 20 x 109/L.
AA was considered very severe (VSAA) if the above
criteria for SAA were fulfilled, and the neutrophil count
was < 0.2 x 109/L.
Moderate AA was defined as a hypo-cellular bone
marrow with at least two of the following haematological
values: neutrophil count < 1 x 109/L, platelet count
< 50 x 109/L or reticulocyte count of < 60 x 109/L.6
Patients not meeting the above criteria were labelled to
have mild AA.6
Patients were treated with HSCT and immuno-
suppressive therapy (IST) which included ATG, steroids,
and cyclosporine; those who received only cyclosporine
and steroids were excluded from the IST regimen. Some
patients got supportive therapy due to financial
constraints. Fanconi’s anemia patients who could not
undergo HSCT were given androgens.
Criteria for response after immunosuppressive therapy
(IST) were divided into complete, partial and no
response. Complete response (CR) was defined as
achieving normal levels of haemoglobin according to
age, platelet count > 100 x 109/L and neutrophil count
> 1.5 x 109/L. Partial response (PR) was defined as
transfusion independence, platelet count > 30 x 109/L,
and neutrophil count > 0.5 x 109/L above baseline. No
response meant neutrophil count < 0.5 x 109/L, platelets
count < 20 x 109/L and transfusions dependence (meet
SAA criteria).6
For HSCT complete response (CR) was increased in the
white cell and platelet count and no response
(engraftment failure) was defined by the return of
peripheral blood cell count to levels meeting the
definition of severe or moderate AA and the requirement
for blood transfusion.7
The mortality and cause of death was noted. Descriptive
statistical analysis was carried out using the SPSS
version 16.0 software. 
RESULTS
Over a period of 9 years, 90 children with AA were
diagnosed. Children up to 15 years of age were
included. The clinicohaematological features are given
in Table I. More than one clinical manifestation was
observed in patients.
Viral serology was done in 56 patients; 2 were positive
for hepatitis B surface antigen and 4 had antibodies
positive to hepatitis C virus.
Congenital Fanconi’s anemia was seen in 15 (16.6%)
patients and rests were acquired, idiopathic aplastic
anemia in 75 (83.4%) patients.
Severity of disease is  given in Table I. Eight patients
(8.9%) underwent HSCT and 12 (13.3%) received IST.
Patients with mild AA were not given any specific
treatment and were observed with weekly blood counts
which normalized within 2-4 weeks (Table II).
Complete response (CR) was seen in 5 and engraftment
failure in 3 patients with HSCT. Among those who
received IST therapy, complete response was seen in
3 (25%), partial response in 5 (41.6%) and no response
in 4 (33.3%). Outcome of patients with HSCT and IST is
shown in Table III.
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Table I: Showing the clinicohaematological features in aplastic anemia.
Patients’ characteristics Number of patients (n=90)
Male / Female 65/25 (72.2%/27.8%)
Median age at diagnosis (years) 8
Presentation 
Fever 65 (72.2%)
Pallor 53 (58.8%)
Skin bleed 49 (54.4%)
Epistaxis 31 (34.4%)
Causes of aplastic anemia 
Fanconi's anemia 15 (16.6%)
Idiopathic 75 (83.4%)
Severity of disease 
Very severe 29 (32.2)
Severe 26 (28.8%)
Moderate 17 (18.8%)
Mild 18 (20%)
Table II: Shows the different treatment and outcome in all patients
with AA.
Treatment n=90
HSCT 8 (8.8%)
IST 
Cyclosporine / ATG/steroids 12 (13.3%)
Cyclosporine / steroids 13 (14.4%)
Androgens 9 (10%)
Supportive 48 (53.3%)
Outcome n=90
Expired 22 (24.4%)
Off treatment 10 (11.1%)
On treatment 3 (3.3%)
Referred out 10 (11.1%)
Lost to follow-up 45 (50%)
Twenty two patients (24.4%) expired; out of whom
16 (72.7%) had infection (fungal in 6, bacterial in 10) and
intracranial bleed in 6 (27.3%). One patient receiving
HSCT and 3 patients receiving IST died due to infection.
DISCUSSION
In this study, children upto the age of 15 years were
included. The median age of 8 years is consistent with
other studies done from different regions.6,8,9 Male
predominance probably reflects gender bias in the
developing world.
The major presenting feature was fever in 71.4%, pallor
in 58.9%, and skin bleed in 54.4% of cases in the current
study which is similar to other studies.8,10
The frequency of Fanconi’s anemia in these patients
was 16.6%, higher than reported in Western literature
but similar to the studies from India.11-13 The increased
incidence of Fanconi’s anemia in this population may be
because of increased consanguinity seen in our country. 
Hepatitis associated AA was seen in 21% of cases.6
Post-hepatitis AA accounts for about 10% of marrow
failure in Western case series.14 In this study as only 56
patients were checked for hepatitis serology, therefore, it
was not possible to determine an overall frequency of
post-hepatitis AA.
The current study showed about approximately two
thirds of patients having SAA and VSAA in 61% and
moderate AA in 18.9% of cases which is similar to
reported elsewhere.6,9 However, Goswami reported
severe and moderate AA in 33.33% and 57.14% of
cases respectively.10
As the expenses of HSCT and IST are high, different
treatment options were discussed with the family.
According to their financial resources, some opted for
transplantation, IST and others remained on supportive
therapy.
CR was seen in 25% and PR in 41.6% in patients who
received IST in the present study. This response does
not match with studies done elsewhere. Pongtanakul
et al. found 62% complete response and 19% partial
response to IST with ATG, CS and steroids for children
with AA.6 A Japanese pediatric series demonstrated an
overall response rate of 65% and complete response
rate of 40% among 60 patients.15 Indeed results have
improved dramatically in children with VSAA from 37%
in the 1980s to 83% in the 1990s.16
HSCT has been shown to have 90% cure rate.17
Matched sibling donor HSCT routinely provide long-term
survival in range of 90%, and 75% of patients respond
to IST.18 In the current study 62.5% of patients who got
HSCT showed complete (CR). Shamsi reported 78%
long-term survival in AA.19 The differences in treatment
given to these patients according to financial resources
may also be a factor for the differences in obtained
results.
The overall mortality was (24.4%), out of which infection
was the predominant cause being found in 72.7% of
patients (45.5% had bacterial and in 27.3% had fungal).
Intracranial bleed was observed in 27.3% of patients. A
German group reported that 11 (13%) patients died
within the 4 months and cause of death was cerebral
haemorrhage in 6 (54.5%) patients and bacterial
infection in 5 (45.5%) patients.20 Infections rate was high
in this study and the deaths occurred within a year of
diagnosis.
The limitations of study is that data was collected retro-
spectively for a period of time, and that the medical
record was the source of information. As a result some
information was missing from the charts.
CONCLUSION
The study shows that the majority of cases with AA are
acquired idiopathic AA and in inherited AA, Fanconi’s
anemia is seen more commonly. VSAA and SAA are
most frequently seen. The response to IST is poor in this
setup in comparison to international data. The outcome
of HSCT in this study was 62.5% which is also low as
compared to international data. 
We recommend that further local studies need to be
done in order to obtain better information with regard to
treatment selection and outcome.
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